HK1126758A1 - Cyclopenta [d] pyrimidines as akt protein kinase inhibitors - Google Patents

Cyclopenta [d] pyrimidines as akt protein kinase inhibitors

Info

Publication number
HK1126758A1
HK1126758A1 HK09105437.1A HK09105437A HK1126758A1 HK 1126758 A1 HK1126758 A1 HK 1126758A1 HK 09105437 A HK09105437 A HK 09105437A HK 1126758 A1 HK1126758 A1 HK 1126758A1
Authority
HK
Hong Kong
Prior art keywords
cyclopenta
pyrimidines
protein kinase
kinase inhibitors
akt protein
Prior art date
Application number
HK09105437.1A
Other languages
English (en)
Inventor
Ian S Mitchell
James F Blake
Rui Xu
Nicholas C Kallan
Dengming Xiao
Keith Lee Spencer
Josef R Bencsik
Jun Liang
Brian Safina
Jun Li
Christine Chabot
Anna L Banka
Eli M Wallace
Stephen T Schlachter
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38686844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1126758(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of HK1126758A1 publication Critical patent/HK1126758A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
HK09105437.1A 2006-07-06 2009-06-17 Cyclopenta [d] pyrimidines as akt protein kinase inhibitors HK1126758A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81876206P 2006-07-06 2006-07-06
PCT/US2007/072876 WO2008006032A1 (en) 2006-07-06 2007-07-05 Cyclopenta [d] pyrimidines as akt protein kinase inhibitors

Publications (1)

Publication Number Publication Date
HK1126758A1 true HK1126758A1 (en) 2009-09-11

Family

ID=38686844

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09105437.1A HK1126758A1 (en) 2006-07-06 2009-06-17 Cyclopenta [d] pyrimidines as akt protein kinase inhibitors

Country Status (32)

Country Link
US (3) US8003651B2 (xx)
EP (1) EP2049500B1 (xx)
JP (3) JP5268904B2 (xx)
KR (2) KR101527232B1 (xx)
CN (2) CN101631778B (xx)
AR (1) AR061844A1 (xx)
AT (1) ATE523499T1 (xx)
AU (1) AU2007269052B2 (xx)
BR (1) BRPI0713555A2 (xx)
CA (1) CA2656618C (xx)
CL (1) CL2007001992A1 (xx)
CO (1) CO6160229A2 (xx)
CR (2) CR10601A (xx)
CY (1) CY1112142T1 (xx)
DK (1) DK2049500T3 (xx)
ES (1) ES2372955T3 (xx)
HK (1) HK1126758A1 (xx)
HR (1) HRP20110882T1 (xx)
IL (1) IL196051A (xx)
MA (1) MA30952B1 (xx)
MX (1) MX2008016203A (xx)
MY (1) MY147628A (xx)
NO (1) NO20090580L (xx)
NZ (1) NZ573979A (xx)
PL (1) PL2049500T3 (xx)
PT (1) PT2049500E (xx)
RS (1) RS52210B (xx)
RU (1) RU2481336C2 (xx)
SI (1) SI2049500T1 (xx)
TW (1) TWI428335B (xx)
UA (1) UA99597C2 (xx)
WO (1) WO2008006032A1 (xx)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA95641C2 (xx) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
ATE532789T1 (de) * 2006-07-06 2011-11-15 Array Biopharma Inc Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
PL2049500T3 (pl) 2006-07-06 2012-02-29 Array Biopharma Inc Cyklopenta[d]pirymidyny jako inhibitory kinaz białkowych AKT
DE602007011628D1 (de) 2006-07-06 2011-02-10 Array Biopharma Inc Dihydrofuropyrimidine als akt-proteinkinaseinhibitoren
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
AU2014201211B2 (en) * 2006-07-06 2016-04-14 Array Biopharma Inc. Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
CN103396409B (zh) * 2007-07-05 2015-03-11 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US8377937B2 (en) 2007-07-05 2013-02-19 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
ES2394759T3 (es) 2008-01-08 2013-02-05 Array Biopharma, Inc. Pirrolopiridinas como inhibidores de quinasa
JP5635910B2 (ja) 2008-01-09 2014-12-03 アレイ バイオファーマ、インコーポレイテッド ＡＫＴタンパク質キナーゼ阻害剤としての５Ｈ−シクロペンタ［ｄ］ピリミジン
JP5512545B2 (ja) 2008-01-09 2014-06-04 アレイ バイオファーマ、インコーポレイテッド Ａｋｔタンパク質キナーゼ阻害剤としてのピリミジルシクロペンタン類
US8835434B2 (en) 2008-01-09 2014-09-16 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
US8853216B2 (en) * 2008-01-09 2014-10-07 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
CN101965347B (zh) 2008-01-09 2013-01-02 阵列生物制药公司 作为激酶抑制剂的吡唑并吡啶
US20100048913A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
JP2012516900A (ja) 2009-02-05 2012-07-26 トーカイ ファーマシューティカルズ，インク． ステロイド性ｃｙｐ１７阻害剤／抗アンドロゲン剤の新しいプロドラッグ
US20100233733A1 (en) * 2009-02-10 2010-09-16 Nodality, Inc., A Delaware Corporation Multiple mechanisms for modulation of the pi3 kinase pathway
EP2558864A1 (en) * 2010-04-16 2013-02-20 Genentech, Inc. Fox03a as predictive biomarker for pi3k/akt kinase pathway inhibitor efficacy
BR112013025353A8 (pt) 2011-04-01 2018-01-02 Genentech Inc combinação de a) um composto de fórmula ia, composto de fórmula ia ou um sal farmaceuticamente aceitável do mesmo, método para tratamento de um distúrbio hiperproliferativo em um mamífero, uso de um composto de fórmula ia ou um sal farmaceuticamente aceitável do mesmo, kit e produto
JP6147246B2 (ja) 2011-04-01 2017-06-14 ジェネンテック， インコーポレイテッド Ａｋｔ及びｍｅｋ阻害剤化合物の組み合わせ、及び使用方法
ES2731833T3 (es) 2012-09-10 2019-11-19 Principia Biopharma Inc Compuestos pirazolopirimidínicos comos inhibidores de cinasas
SG11201507093WA (en) 2013-03-14 2015-10-29 Univ Maryland Baltimore Office Of Technology Transfer Androgen receptor down-regulating agents and uses thereof
WO2015013579A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Compositions to improve the therapeutic benefit of bisantrene
RU2016104643A (ru) 2013-08-12 2017-09-19 Токай Фармасьютикалз, Инк. Биомаркёры для лечения неопластических заболеваний с применением нацеленных на андроген методов лечения
KR20220139440A (ko) * 2013-11-15 2022-10-14 에프. 호프만-라 로슈 아게 피리미딘일사이클로펜테인 화합물의 제조 방법
US10092569B2 (en) 2014-02-21 2018-10-09 Principia Biopharma Inc. Salts and solid form of a BTK inhibitor
JP2017530948A (ja) * 2014-08-27 2017-10-19 ペプティメド， インコーポレイテッド 抗腫瘍組成物および方法
MX2017007973A (es) 2014-12-18 2018-02-09 Principia Biopharma Inc Tratamiento de penfigo.
MA42242A (fr) 2015-06-24 2018-05-02 Principia Biopharma Inc Inhibiteurs de la tyrosine kinase
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
AU2017290354C1 (en) 2016-06-29 2023-07-06 Principia Biopharma Inc. Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
CA3092677A1 (en) * 2018-03-06 2019-09-12 Icahn School Of Medicine At Mount Sinai Serine threonine kinase (akt) degradation / disruption compounds and methods of use
TWI830733B (zh) * 2018-05-11 2024-02-01 中國大陸商迪哲（江蘇）醫藥有限公司 環戊烷化合物
IT201800005561A1 (it) * 2018-05-21 2019-11-21 Metodo per la pulizia dei denti mediante una composizione in polvere a base di idrossiapatite.
KR20210120054A (ko) 2019-01-29 2021-10-06 난징 치아 타이 티안큉 파마슈티컬 컴파니 리미티드 Akt 억제제
CN115485276B (zh) * 2020-05-15 2024-05-31 南京正大天晴制药有限公司 氘代akt激酶抑制剂
JP2023534551A (ja) * 2020-07-22 2023-08-09 南京正大天晴制薬有限公司 Ａｋｔ阻害剤の単位剤形組成物
WO2022017449A1 (zh) 2020-07-22 2022-01-27 南京正大天晴制药有限公司 一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐、其制备方法及用途
WO2023109540A1 (zh) * 2021-12-17 2023-06-22 中国医药研究开发中心有限公司 具有akt激酶抑制活性的杂环化合物及其制备方法和医药用途

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3885035A (en) 1972-04-05 1975-05-20 Sandoz Ag Method for treating arrhythmia by using 1,4-bis(4 quinazolinyl) piperazines
US3956495A (en) 1973-10-30 1976-05-11 Eli Lilly And Company 2,4-Diaminoquinazolines as antithrombotic agents
US3966936A (en) 1974-02-21 1976-06-29 Pfizer Inc. Piperazino quinazoline bronchodilators
US4060615A (en) 1976-02-18 1977-11-29 Mead Johnson & Company 2-Piperazinyl-6,7-dimethoxyquinazolines
US4051412A (en) * 1976-09-02 1977-09-27 General Electric Company Discharge lamp operating circuit
JPS562968A (en) 1979-06-21 1981-01-13 Mitsubishi Yuka Yakuhin Kk Novel pyrimidine derivative
US4749704A (en) 1985-03-07 1988-06-07 Sankyo Company Limited Cyclopenta[d]pyrimidine derivatives and use as antidepressants
EP0257102B1 (en) 1986-02-24 1997-11-19 Mitsui Petrochemical Industries, Ltd. Agents for treating neurophathy
US4871739A (en) 1987-01-21 1989-10-03 Merck & Co., Inc. Substituted 6H-7,8-dihydrothiapyrano(3,2-D)-pyrimidines as hyopglycemic agents
US4889856A (en) 1987-08-31 1989-12-26 Merck & Co., Inc. 7,8-dihydro-4-(1-pierazinyl)-6H-thiopyrano-[3,2-d] pyrimidines as β-blockers
US4994464A (en) 1987-08-31 1991-02-19 Merck & Co., Inc. Piperazinylpyrimidines as β-adrenergic receptor blockers
MX19185A (es) 1989-01-20 1993-12-01 Pfizer Procedimiento para preparar 3-(1,2,5,6-tretrahidropiridil)-pirrolopiridinas.
EP0664291B1 (en) 1992-10-05 2000-07-19 Ube Industries, Ltd. Pyrimidine compound
WO1995003286A1 (fr) 1993-07-23 1995-02-02 The Green Cross Corporation Derive de triazole et son utilisation pharmaceutique
GB9416189D0 (en) 1994-08-10 1994-09-28 Merck Sharp & Dohme Therapeutic agents
DE69530989T2 (de) 1994-08-13 2004-05-19 Yuhan Corp. Neue pyrimidinderivate und verfahren zu ihrer herstellung
US5525625A (en) 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
US7067664B1 (en) 1995-06-06 2006-06-27 Pfizer Inc. Corticotropin releasing factor antagonists
ZA979961B (en) 1996-11-15 1999-05-05 Lilly Co Eli 5-HT1F agonists
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
IL132840A (en) 1997-07-01 2004-12-15 Warner Lambert Co Derivatives 4 - bromo or 4 - benzohydroxamic acid iodine amino iodine and pharmaceutical preparations containing them for use as MEK inhibitors
KR20010014360A (ko) 1997-07-01 2001-02-26 로즈 암스트롱, 크리스틴 에이. 트러트웨인 2-(4-브로모 또는 4-요오도 페닐아미노)벤조산 유도체 및ｍｅｋ 억제제로서의 그의 용도
US6821963B2 (en) 1997-07-01 2004-11-23 Warner-Lambert Company 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
US6506798B1 (en) 1997-07-01 2003-01-14 Warner-Lambert Company 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
US6310060B1 (en) 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
CA2326324C (en) 1998-03-31 2010-05-11 Kyowa Hakko Kogyo Co., Ltd. Nitrogen-containing heterocyclic compound
DE19853278A1 (de) 1998-11-19 2000-05-25 Aventis Pharma Gmbh Substituierte 4-Amino-2-aryl-cyclopenta[d]pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
WO2000040235A2 (en) 1999-01-07 2000-07-13 Warner-Lambert Company Treatment of asthma with mek inhibitors
AU2203800A (en) 1999-01-07 2000-07-24 Warner-Lambert Company Antiviral method using mek inhibitors
JP2002534446A (ja) 1999-01-13 2002-10-15 ワーナー−ランバート・カンパニー ４′ヘテロアリールジアリールアミン
CA2348236A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
CA2349467A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors
JP4621355B2 (ja) 1999-01-13 2011-01-26 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー ベンゾ複素環およびｍｅｋ阻害剤としてのその使用
CA2349832A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
DE69926914T2 (de) 1999-01-13 2006-06-29 Warner-Lambert Co. Llc 1-heterozyklus-substituierte diarylaminen
GB9910577D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
AU5785900A (en) 1999-07-16 2001-02-05 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
JP2003504400A (ja) 1999-07-16 2003-02-04 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤を用いた慢性痛の治療方法
KR20020016899A (ko) 1999-07-16 2002-03-06 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Ｍｅｋ 억제제를 사용한 만성 동통의 치료 방법
HUP0202319A3 (en) 1999-07-16 2004-12-28 Warner Lambert Co Use of mek inhibitors for the preparation of pharmaceutical compositions treating chronic pain
GB0003636D0 (en) * 2000-02-16 2000-04-05 Smithkline Beecham Plc Novel compounds
JP2003527379A (ja) 2000-03-15 2003-09-16 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Ｍｅｘ阻害物質としての５−アミド置換ジアリールアミン類
ES2461854T3 (es) 2000-07-19 2014-05-21 Warner-Lambert Company Llc Ésteres oxigenados de ácidos 4-yodofenilamino-benzhidroxámicos
CA2420003A1 (en) 2000-08-25 2002-03-07 Derick Dale Winkle Process for making n-aryl-anthranilic acids and their derivatives
EP1317444B1 (en) 2000-09-15 2006-05-31 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
JP2004514718A (ja) 2000-11-02 2004-05-20 アストラゼネカ　アクチボラグ 抗癌剤としての置換キノリン類
WO2002083139A1 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
RU2003134646A (ru) * 2001-04-30 2005-04-20 Глэксо Груп Лимитед (GB) Конденсированные пиримидины в качестве антагонистов кортикотропинвысокобождающего фактора (crf)
CN1649848A (zh) 2001-04-30 2005-08-03 葛兰素集团有限公司 作为促肾上腺皮质激素释放因子(crf)拮抗剂的稠合嘧啶衍生物
US7115741B2 (en) 2001-09-06 2006-10-03 Levy Daniel E 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds
WO2003049678A2 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
CA2473510A1 (en) 2002-01-23 2003-07-31 Bayer Pharmaceuticals Corporation Pyrimidine derivatives as rho-kinase inhibitors
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
AU2003220202A1 (en) 2002-03-13 2003-09-29 Array Biopharma, Inc N3 alkylated benzimidazole derivatives as mek inhibitors
EP2275102B1 (en) 2002-03-13 2015-07-29 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
US7273869B2 (en) 2002-04-08 2007-09-25 Merck & Co., Inc. Inhibitors of Akt activity
CA2480880C (en) 2002-04-08 2011-03-22 Merck & Co., Inc. Inhibitors of akt activity
WO2003086394A1 (en) 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibitors of akt activity
AU2003226250B2 (en) 2002-04-08 2007-08-16 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
MXPA04011093A (es) 2002-05-10 2005-02-14 Neurocrine Biosciences Inc Piperazina sustituida como ligandos de receptores de melanocortina.
CA2501365C (en) 2002-10-30 2011-05-31 Merck & Co., Inc. Inhibitors of akt activity
US20040102360A1 (en) 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
WO2004048343A1 (en) 2002-11-28 2004-06-10 Schering Aktiengesellschaft Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
CN1809351A (zh) 2003-04-24 2006-07-26 麦克公司 Akt活性抑制剂
US6994380B2 (en) * 2003-06-02 2006-02-07 Cooke Jr Charles M High pressure quick connect coupling and seal
EP1646615B1 (en) 2003-06-06 2009-08-26 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
JP4808156B2 (ja) 2003-08-05 2011-11-02 バーテックス ファーマシューティカルズ インコーポレイテッド 電位依存型イオンチャネルの阻害剤としての縮合ピリミジン化合物
ATE374190T1 (de) 2003-08-12 2007-10-15 Hoffmann La Roche Tetrahydrochinazolinderivate als cfr-antagonisten
US20070027156A1 (en) 2003-09-09 2007-02-01 Hisao Nakai Crf antagonists and heterobicyclic compounds
US20050182061A1 (en) 2003-10-02 2005-08-18 Jeremy Green Phthalimide compounds useful as protein kinase inhibitors
RU2006121990A (ru) * 2003-11-21 2007-12-27 Эррэй Биофарма Инк. (Us) Ингибиторы протеинкиназ акт
EP1750727A2 (en) 2004-04-23 2007-02-14 Exelixis, Inc. Kinase modulators and methods of use
MXPA06014747A (es) 2004-06-28 2007-02-16 Altana Pharma Ag Pirimidinas 4,6-disustituidas y su uso como inhibidores de proteina cinasa.
US20060025074A1 (en) 2004-07-30 2006-02-02 Chih-Ming Liang Bluetooth-based headset
TWM266655U (en) 2004-09-23 2005-06-01 Blueexpert Technology Corp Bluetooth earphone device capable of wirelessly receiving and transmitting stereo sound signal and digital information signal
TW200621257A (en) * 2004-10-20 2006-07-01 Astellas Pharma Inc Pyrimidine derivative fused with nonaromatic ring
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
CA2590961C (en) 2004-12-28 2013-11-26 Exelixis, Inc. [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
JP2008531542A (ja) 2005-02-24 2008-08-14 ファイザー・プロダクツ・インク 抗癌剤として有用な二環式複素芳香族誘導体
ZA200710379B (en) 2005-05-20 2009-05-27 Vertex Pharma Pyrrolopyridines useful as inhibitors of protein kinase
UY29610A1 (es) 2005-06-21 2007-01-31 Cancer Rec Tech Ltd Aril-alquilaminas y heteroaril-alquilaminas como inhibidores de la quinasa proteínica
WO2007042298A1 (en) 2005-10-13 2007-04-19 Glaxo Group Limited Pyrrolopyrimidine derivatives as syk inhibitors
JP2009523701A (ja) 2005-12-28 2009-06-25 武田薬品工業株式会社 縮合複素環化合物およびその用途
US20090124610A1 (en) 2006-04-25 2009-05-14 Gordon Saxty Pharmaceutical compounds
RU2008152171A (ru) 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
GB0613518D0 (en) 2006-07-06 2006-08-16 Phytopharm Plc Chemical compounds
PL2049500T3 (pl) 2006-07-06 2012-02-29 Array Biopharma Inc Cyklopenta[d]pirymidyny jako inhibitory kinaz białkowych AKT
TW200808325A (en) 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
UA95641C2 (xx) 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
UA100227C2 (uk) 2006-07-06 2012-12-10 Глаксо Груп Лімітед Заміщені n-фенілметил-5-оксопролін-2-аміди як антагоністи p2x7-рецептора та їх застосування
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents

Also Published As

Publication number Publication date
DK2049500T3 (da) 2011-12-12
JP2013209381A (ja) 2013-10-10
UA99597C2 (xx) 2012-09-10
US8846681B2 (en) 2014-09-30
CR20140215A (es) 2014-07-11
NO20090580L (no) 2009-04-06
MY147628A (en) 2012-12-31
AU2007269052B2 (en) 2014-10-23
US20110245230A1 (en) 2011-10-06
AU2007269052A1 (en) 2008-01-10
CN101631778A (zh) 2010-01-20
CA2656618C (en) 2014-08-26
US20140349996A1 (en) 2014-11-27
TW200817372A (en) 2008-04-16
AR061844A1 (es) 2008-09-24
RU2481336C2 (ru) 2013-05-10
CO6160229A2 (es) 2010-05-20
CN103288753A (zh) 2013-09-11
PL2049500T3 (pl) 2012-02-29
US8003651B2 (en) 2011-08-23
KR20150041164A (ko) 2015-04-15
JP5268904B2 (ja) 2013-08-21
HRP20110882T1 (hr) 2012-01-31
KR101527232B1 (ko) 2015-06-09
SI2049500T1 (sl) 2012-01-31
MA30952B1 (fr) 2009-12-01
CR10601A (es) 2009-02-20
ES2372955T3 (es) 2012-01-30
CA2656618A1 (en) 2008-01-10
US20080058327A1 (en) 2008-03-06
IL196051A (en) 2012-10-31
ATE523499T1 (de) 2011-09-15
EP2049500A1 (en) 2009-04-22
RS52210B (en) 2012-10-31
RU2009103899A (ru) 2010-08-20
JP2009542721A (ja) 2009-12-03
TWI428335B (zh) 2014-03-01
WO2008006032A1 (en) 2008-01-10
IL196051A0 (en) 2009-09-01
KR20090029287A (ko) 2009-03-20
PT2049500E (pt) 2011-12-23
CL2007001992A1 (es) 2008-07-18
EP2049500B1 (en) 2011-09-07
NZ573979A (en) 2012-02-24
JP2013231040A (ja) 2013-11-14
CN101631778B (zh) 2013-05-08
MX2008016203A (es) 2009-01-27
JP5586735B2 (ja) 2014-09-10
BRPI0713555A2 (pt) 2012-03-20
CY1112142T1 (el) 2015-11-04

Similar Documents

Publication Publication Date Title
IL196051A0 (en) Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
HK1160134A1 (en) Hydroxylated cyclopenta[d]pyrimidines as akt protein kinase inhibitors akt [d]
HK1150605A1 (en) 5h-cyclopenta[d]pyrimidines as akt protein kinase inhibitors
EP2497470B8 (en) Imidazotriazines and imidazopyrimidines as kinase inhibitors
ZA200809796B (en) Pyrazolo [1,5-A]pyrimidines as CDK inhibitors
HK1146042A1 (en) Pyrimidine derivatives as protein kinase inhibitors
HK1115879A1 (en) Pyrrolo [3,2-c] pyridine-4-one 2-indolinone protein kinase inhibitors
ZA201002318B (en) Pyrrolo [2,3-d]pyrimidin derivatives as protein kinase b inhibitors
HK1158947A1 (en) Macrocyclic pyrimidines as protein kinase inhibitors
HK1147255A1 (en) Pyrimidyl cyclopentanes as akt protein kinase inhibitors
ZA200901593B (en) Pyrimidines derivatives and their use as kinase inhibitors
IL195005A0 (en) Inhibitors of akt (protein kinase b)
IL199378A0 (en) 2-substituted-6-heterocyclic pyrimidone derivatives as tau protein kinase 1 inhibitors
ZA200807490B (en) Thiazolyldihydroindazole derivatives as protein kinase inhibitors
ZA200810573B (en) Substituted 3-cyanopyridines as protein kinase inhibitors
ZA200809545B (en) Inhibitors of Akt (protein kinase B)

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200705